A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

NCT00333008 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma
Lymphoma, Non-Hodgkin

Interventions

DRUG: Doxil
DRUG: Cyclophosphamide
DRUG: Vincristine
DRUG: Prednisone
DRUG: Rituximab
DRUG: Pegfilgrastim

Sponsor

The Alvin and Lois Lapidus Cancer Institute

Collaborators

[object Object]